Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus

Service des Maladies Infectieuses et Tropicales, Hôpital Saint Louis, Paris, France.
Clinical Infectious Diseases (Impact Factor: 9.42). 11/2004; 39(7):1062-4. DOI: 10.1086/424012
Source: PubMed

ABSTRACT We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir. The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Solid organ transplant may be the only therapeutic alternative in some HIV-infected patients. Experience in North America and Europe during the last five years shows that survival at three years after an organ transplant is similar to that observed in HIV-negative patients. The criteria agreed upon to select HIV patients for transplant are: no opportunistic infections (except tuberculosis, oesophageal candidiasis or P. jiroveci -previously carinii- pneumonia), CD4 lymphocyte count above 200 cells/.L (100 cells/.L in the case of liver transplant) and an HIV viral load which is undetectable or suppressible with antiretroviral therapy. Another criterion is a two-year abstinence from heroin and cocaine, although the patient may be in a methadone programme. The main problems in the post-transplant period are pharmacokinetic and pharmacodynamic interactions between antiretorivirals and immunosuppressors, rejection and the management of relapse of HCV infection, which is one of the main causes of post-liver transplant mortality. Up to now, experience with pegylated interferon and ribavirin is scarce in this population. The English version of the manuscript is available at
    Enfermedades Infecciosas y Microbiología Clínica 23(6):353-62. · 1.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Coinfection with HIV and viral hepatitis substantially alters the natural course of viral hepatitis as well as its management. Therapy for infection with hepatitis B virus (HBV) in HIV-coinfected patients requires consideration of several factors, such as whether the antiviral activity of a particular agent is specific for HBV or for both viruses, the potential for drug resistance and cross-resistance, and the potential for hepatotoxicity. In most trials, response to treatment for infection with the hepatitis C virus (HCV) seems to be lower in HCV/HIV-coinfected patients than in those infected with HCV alone. Despite the current recommendations for treating hepatitis C in the setting of HIV, a large percentage of patients do not receive therapy.
    Current Hepatitis Reports 08/2009; 6(3):103-113. DOI:10.1007/s11901-007-0012-9
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic Hepatitis B, were considered in the development of these guidelines.3-7 The recommendations suggest pre- ferred approaches to the diagnostic, therapeutic, and pre- ventive aspects of care. They are intended to be flexible. Specific recommendations are based on relevant pub- lished information. In an attempt to characterize the qual- ity of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a category to be assigned and reported with each recommendation (Table 1). These guidelines may be updated periodically as new information becomes available.